Fracture risk and survival outcomes in metastatic castration-resistant prostate cancer patients sequentially treated with abiraterone acetate and RADIUM-223
Purpose To evaluate the fracture risk and survival outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC) who received sequentially abiraterone acetate (AA) and radium 223 [223Ra]RaCl 2 in the daily clinical practice. Materials We retrospectively reviewed the records of mC...
Gespeichert in:
| Veröffentlicht in: | European journal of nuclear medicine and molecular imaging 2020-10, Vol.47 (11), p.2633-2638 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2638 |
|---|---|
| container_issue | 11 |
| container_start_page | 2633 |
| container_title | European journal of nuclear medicine and molecular imaging |
| container_volume | 47 |
| creator | Caffo, Orazio Frantellizzi, Viviana Tucci, Marcello Galli, Luca Monari, Fabio Baldari, Sergio Masini, Cristina Bortolus, Roberto Facchini, Gaetano Alongi, Pierpaolo Agostini, Stefania Zichi, Clizia Biasco, Elisa Fanti, Stefano Pignata, Salvatore Filice, Angelina Borsatti, Eugenio Rossetti, Sabrina Spada, Massimiliano Cortesi, Enrico De Vincentis, Giuseppe |
| description | Purpose
To evaluate the fracture risk and survival outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC) who received sequentially abiraterone acetate (AA) and radium 223 [223Ra]RaCl
2
in the daily clinical practice.
Materials
We retrospectively reviewed the records of mCRPC patients who received [223Ra]RaCl
2
immediately after progressing during an AA treatment line in everyday clinical practice.
Results
We reviewed data of a consecutive series of 94 mCRPC patients. Most of the patients (85.1%) received [223Ra]RaCl
2
as second- or third-line treatment. [223Ra]RaCl
2
treatment was well-tolerated; there were only four cases of grade 3 anaemia, two cases of grade 3 leukopenia and one case of grade 3 neutropenia. The overall fracture rate is 2.1%; one fracture was recorded during the course of [223Ra]RaCl
2
treatment, and one was recorded 1 month after its end. The fractures both occurred at metastatic sites. Median OS from [223Ra]RaCl
2
start was more than 14 months regardless of the treatment line when [223Ra]RaCl
2
was administered.
Conclusion
The findings of this study show that the treatment with [223Ra]RaCl
2
immediately after AA was active and safe with a very low risk of a fracture. Thus, the present observational report makes a valuable contribution to the current debate concerning the risks and benefits of including [223Ra]RaCl
2
in the therapeutic algorithm. |
| doi_str_mv | 10.1007/s00259-020-04796-w |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2386437740</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2386437740</sourcerecordid><originalsourceid>FETCH-LOGICAL-c347t-d62ac9aecc38953cd8e4c295d38799b60b725cd9fb684156987a067846fa2e463</originalsourceid><addsrcrecordid>eNp9UUtvFSEYJUZjH_oHXBiWblAGGB7LplptUmNi7JowzHeVOsNcgelN_4s_1u_2tl264oTzgJNDyJuOv-84Nx8q56J3jAvOuDJOs90zctzpzjHDrXv-hA0_Iie13nDeWWHdS3IkhVBOqv6Y_L0oIba1AC2p_qYhj7Su5Tbdhokua4vLDJWmTGdoobbQUqQRQUG0ZFagJrzNjW7LsqcB2Ryh0C0KILdKK_xZEaQwTXe0FUDNSHep_aJhSBgDZclAQ4R79_7972cfL6-_MiHkK_JiE6YKrx_OU3J98enH-Rd29e3z5fnZFYtSmcZGLUJ0AWKU1vUyjhZUFK4fpTXODZoPRvRxdJtBW9X12lkTuDZW6U0QoLQ8Je8OudgCf1ubn1ONME0hw7JWL6TVShqjOErFQRqxcC2w8duS5lDufMf9fhV_WMXjKv5-Fb9D09uH_HWYYXyyPM6AAnkQVKTyTyj-ZllLxs7_i_0HMKmcHQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2386437740</pqid></control><display><type>article</type><title>Fracture risk and survival outcomes in metastatic castration-resistant prostate cancer patients sequentially treated with abiraterone acetate and RADIUM-223</title><source>MEDLINE</source><source>Springer Online Journals</source><creator>Caffo, Orazio ; Frantellizzi, Viviana ; Tucci, Marcello ; Galli, Luca ; Monari, Fabio ; Baldari, Sergio ; Masini, Cristina ; Bortolus, Roberto ; Facchini, Gaetano ; Alongi, Pierpaolo ; Agostini, Stefania ; Zichi, Clizia ; Biasco, Elisa ; Fanti, Stefano ; Pignata, Salvatore ; Filice, Angelina ; Borsatti, Eugenio ; Rossetti, Sabrina ; Spada, Massimiliano ; Cortesi, Enrico ; De Vincentis, Giuseppe</creator><creatorcontrib>Caffo, Orazio ; Frantellizzi, Viviana ; Tucci, Marcello ; Galli, Luca ; Monari, Fabio ; Baldari, Sergio ; Masini, Cristina ; Bortolus, Roberto ; Facchini, Gaetano ; Alongi, Pierpaolo ; Agostini, Stefania ; Zichi, Clizia ; Biasco, Elisa ; Fanti, Stefano ; Pignata, Salvatore ; Filice, Angelina ; Borsatti, Eugenio ; Rossetti, Sabrina ; Spada, Massimiliano ; Cortesi, Enrico ; De Vincentis, Giuseppe</creatorcontrib><description>Purpose
To evaluate the fracture risk and survival outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC) who received sequentially abiraterone acetate (AA) and radium 223 [223Ra]RaCl
2
in the daily clinical practice.
Materials
We retrospectively reviewed the records of mCRPC patients who received [223Ra]RaCl
2
immediately after progressing during an AA treatment line in everyday clinical practice.
Results
We reviewed data of a consecutive series of 94 mCRPC patients. Most of the patients (85.1%) received [223Ra]RaCl
2
as second- or third-line treatment. [223Ra]RaCl
2
treatment was well-tolerated; there were only four cases of grade 3 anaemia, two cases of grade 3 leukopenia and one case of grade 3 neutropenia. The overall fracture rate is 2.1%; one fracture was recorded during the course of [223Ra]RaCl
2
treatment, and one was recorded 1 month after its end. The fractures both occurred at metastatic sites. Median OS from [223Ra]RaCl
2
start was more than 14 months regardless of the treatment line when [223Ra]RaCl
2
was administered.
Conclusion
The findings of this study show that the treatment with [223Ra]RaCl
2
immediately after AA was active and safe with a very low risk of a fracture. Thus, the present observational report makes a valuable contribution to the current debate concerning the risks and benefits of including [223Ra]RaCl
2
in the therapeutic algorithm.</description><identifier>ISSN: 1619-7070</identifier><identifier>EISSN: 1619-7089</identifier><identifier>DOI: 10.1007/s00259-020-04796-w</identifier><identifier>PMID: 32249345</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Abiraterone Acetate - adverse effects ; Bone Neoplasms - drug therapy ; Cardiology ; Humans ; Imaging ; Male ; Medicine ; Medicine & Public Health ; Nuclear Medicine ; Oncology ; Oncology – Genitourinary ; Original Article ; Orthopedics ; Prostatic Neoplasms, Castration-Resistant - drug therapy ; Radiology ; Radium - adverse effects ; Retrospective Studies ; Treatment Outcome</subject><ispartof>European journal of nuclear medicine and molecular imaging, 2020-10, Vol.47 (11), p.2633-2638</ispartof><rights>Springer-Verlag GmbH Germany, part of Springer Nature 2020</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c347t-d62ac9aecc38953cd8e4c295d38799b60b725cd9fb684156987a067846fa2e463</citedby><cites>FETCH-LOGICAL-c347t-d62ac9aecc38953cd8e4c295d38799b60b725cd9fb684156987a067846fa2e463</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00259-020-04796-w$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00259-020-04796-w$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32249345$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Caffo, Orazio</creatorcontrib><creatorcontrib>Frantellizzi, Viviana</creatorcontrib><creatorcontrib>Tucci, Marcello</creatorcontrib><creatorcontrib>Galli, Luca</creatorcontrib><creatorcontrib>Monari, Fabio</creatorcontrib><creatorcontrib>Baldari, Sergio</creatorcontrib><creatorcontrib>Masini, Cristina</creatorcontrib><creatorcontrib>Bortolus, Roberto</creatorcontrib><creatorcontrib>Facchini, Gaetano</creatorcontrib><creatorcontrib>Alongi, Pierpaolo</creatorcontrib><creatorcontrib>Agostini, Stefania</creatorcontrib><creatorcontrib>Zichi, Clizia</creatorcontrib><creatorcontrib>Biasco, Elisa</creatorcontrib><creatorcontrib>Fanti, Stefano</creatorcontrib><creatorcontrib>Pignata, Salvatore</creatorcontrib><creatorcontrib>Filice, Angelina</creatorcontrib><creatorcontrib>Borsatti, Eugenio</creatorcontrib><creatorcontrib>Rossetti, Sabrina</creatorcontrib><creatorcontrib>Spada, Massimiliano</creatorcontrib><creatorcontrib>Cortesi, Enrico</creatorcontrib><creatorcontrib>De Vincentis, Giuseppe</creatorcontrib><title>Fracture risk and survival outcomes in metastatic castration-resistant prostate cancer patients sequentially treated with abiraterone acetate and RADIUM-223</title><title>European journal of nuclear medicine and molecular imaging</title><addtitle>Eur J Nucl Med Mol Imaging</addtitle><addtitle>Eur J Nucl Med Mol Imaging</addtitle><description>Purpose
To evaluate the fracture risk and survival outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC) who received sequentially abiraterone acetate (AA) and radium 223 [223Ra]RaCl
2
in the daily clinical practice.
Materials
We retrospectively reviewed the records of mCRPC patients who received [223Ra]RaCl
2
immediately after progressing during an AA treatment line in everyday clinical practice.
Results
We reviewed data of a consecutive series of 94 mCRPC patients. Most of the patients (85.1%) received [223Ra]RaCl
2
as second- or third-line treatment. [223Ra]RaCl
2
treatment was well-tolerated; there were only four cases of grade 3 anaemia, two cases of grade 3 leukopenia and one case of grade 3 neutropenia. The overall fracture rate is 2.1%; one fracture was recorded during the course of [223Ra]RaCl
2
treatment, and one was recorded 1 month after its end. The fractures both occurred at metastatic sites. Median OS from [223Ra]RaCl
2
start was more than 14 months regardless of the treatment line when [223Ra]RaCl
2
was administered.
Conclusion
The findings of this study show that the treatment with [223Ra]RaCl
2
immediately after AA was active and safe with a very low risk of a fracture. Thus, the present observational report makes a valuable contribution to the current debate concerning the risks and benefits of including [223Ra]RaCl
2
in the therapeutic algorithm.</description><subject>Abiraterone Acetate - adverse effects</subject><subject>Bone Neoplasms - drug therapy</subject><subject>Cardiology</subject><subject>Humans</subject><subject>Imaging</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Nuclear Medicine</subject><subject>Oncology</subject><subject>Oncology – Genitourinary</subject><subject>Original Article</subject><subject>Orthopedics</subject><subject>Prostatic Neoplasms, Castration-Resistant - drug therapy</subject><subject>Radiology</subject><subject>Radium - adverse effects</subject><subject>Retrospective Studies</subject><subject>Treatment Outcome</subject><issn>1619-7070</issn><issn>1619-7089</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9UUtvFSEYJUZjH_oHXBiWblAGGB7LplptUmNi7JowzHeVOsNcgelN_4s_1u_2tl264oTzgJNDyJuOv-84Nx8q56J3jAvOuDJOs90zctzpzjHDrXv-hA0_Iie13nDeWWHdS3IkhVBOqv6Y_L0oIba1AC2p_qYhj7Su5Tbdhokua4vLDJWmTGdoobbQUqQRQUG0ZFagJrzNjW7LsqcB2Ryh0C0KILdKK_xZEaQwTXe0FUDNSHep_aJhSBgDZclAQ4R79_7972cfL6-_MiHkK_JiE6YKrx_OU3J98enH-Rd29e3z5fnZFYtSmcZGLUJ0AWKU1vUyjhZUFK4fpTXODZoPRvRxdJtBW9X12lkTuDZW6U0QoLQ8Je8OudgCf1ubn1ONME0hw7JWL6TVShqjOErFQRqxcC2w8duS5lDufMf9fhV_WMXjKv5-Fb9D09uH_HWYYXyyPM6AAnkQVKTyTyj-ZllLxs7_i_0HMKmcHQ</recordid><startdate>20201001</startdate><enddate>20201001</enddate><creator>Caffo, Orazio</creator><creator>Frantellizzi, Viviana</creator><creator>Tucci, Marcello</creator><creator>Galli, Luca</creator><creator>Monari, Fabio</creator><creator>Baldari, Sergio</creator><creator>Masini, Cristina</creator><creator>Bortolus, Roberto</creator><creator>Facchini, Gaetano</creator><creator>Alongi, Pierpaolo</creator><creator>Agostini, Stefania</creator><creator>Zichi, Clizia</creator><creator>Biasco, Elisa</creator><creator>Fanti, Stefano</creator><creator>Pignata, Salvatore</creator><creator>Filice, Angelina</creator><creator>Borsatti, Eugenio</creator><creator>Rossetti, Sabrina</creator><creator>Spada, Massimiliano</creator><creator>Cortesi, Enrico</creator><creator>De Vincentis, Giuseppe</creator><general>Springer Berlin Heidelberg</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20201001</creationdate><title>Fracture risk and survival outcomes in metastatic castration-resistant prostate cancer patients sequentially treated with abiraterone acetate and RADIUM-223</title><author>Caffo, Orazio ; Frantellizzi, Viviana ; Tucci, Marcello ; Galli, Luca ; Monari, Fabio ; Baldari, Sergio ; Masini, Cristina ; Bortolus, Roberto ; Facchini, Gaetano ; Alongi, Pierpaolo ; Agostini, Stefania ; Zichi, Clizia ; Biasco, Elisa ; Fanti, Stefano ; Pignata, Salvatore ; Filice, Angelina ; Borsatti, Eugenio ; Rossetti, Sabrina ; Spada, Massimiliano ; Cortesi, Enrico ; De Vincentis, Giuseppe</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c347t-d62ac9aecc38953cd8e4c295d38799b60b725cd9fb684156987a067846fa2e463</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Abiraterone Acetate - adverse effects</topic><topic>Bone Neoplasms - drug therapy</topic><topic>Cardiology</topic><topic>Humans</topic><topic>Imaging</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Nuclear Medicine</topic><topic>Oncology</topic><topic>Oncology – Genitourinary</topic><topic>Original Article</topic><topic>Orthopedics</topic><topic>Prostatic Neoplasms, Castration-Resistant - drug therapy</topic><topic>Radiology</topic><topic>Radium - adverse effects</topic><topic>Retrospective Studies</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Caffo, Orazio</creatorcontrib><creatorcontrib>Frantellizzi, Viviana</creatorcontrib><creatorcontrib>Tucci, Marcello</creatorcontrib><creatorcontrib>Galli, Luca</creatorcontrib><creatorcontrib>Monari, Fabio</creatorcontrib><creatorcontrib>Baldari, Sergio</creatorcontrib><creatorcontrib>Masini, Cristina</creatorcontrib><creatorcontrib>Bortolus, Roberto</creatorcontrib><creatorcontrib>Facchini, Gaetano</creatorcontrib><creatorcontrib>Alongi, Pierpaolo</creatorcontrib><creatorcontrib>Agostini, Stefania</creatorcontrib><creatorcontrib>Zichi, Clizia</creatorcontrib><creatorcontrib>Biasco, Elisa</creatorcontrib><creatorcontrib>Fanti, Stefano</creatorcontrib><creatorcontrib>Pignata, Salvatore</creatorcontrib><creatorcontrib>Filice, Angelina</creatorcontrib><creatorcontrib>Borsatti, Eugenio</creatorcontrib><creatorcontrib>Rossetti, Sabrina</creatorcontrib><creatorcontrib>Spada, Massimiliano</creatorcontrib><creatorcontrib>Cortesi, Enrico</creatorcontrib><creatorcontrib>De Vincentis, Giuseppe</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of nuclear medicine and molecular imaging</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Caffo, Orazio</au><au>Frantellizzi, Viviana</au><au>Tucci, Marcello</au><au>Galli, Luca</au><au>Monari, Fabio</au><au>Baldari, Sergio</au><au>Masini, Cristina</au><au>Bortolus, Roberto</au><au>Facchini, Gaetano</au><au>Alongi, Pierpaolo</au><au>Agostini, Stefania</au><au>Zichi, Clizia</au><au>Biasco, Elisa</au><au>Fanti, Stefano</au><au>Pignata, Salvatore</au><au>Filice, Angelina</au><au>Borsatti, Eugenio</au><au>Rossetti, Sabrina</au><au>Spada, Massimiliano</au><au>Cortesi, Enrico</au><au>De Vincentis, Giuseppe</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Fracture risk and survival outcomes in metastatic castration-resistant prostate cancer patients sequentially treated with abiraterone acetate and RADIUM-223</atitle><jtitle>European journal of nuclear medicine and molecular imaging</jtitle><stitle>Eur J Nucl Med Mol Imaging</stitle><addtitle>Eur J Nucl Med Mol Imaging</addtitle><date>2020-10-01</date><risdate>2020</risdate><volume>47</volume><issue>11</issue><spage>2633</spage><epage>2638</epage><pages>2633-2638</pages><issn>1619-7070</issn><eissn>1619-7089</eissn><abstract>Purpose
To evaluate the fracture risk and survival outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC) who received sequentially abiraterone acetate (AA) and radium 223 [223Ra]RaCl
2
in the daily clinical practice.
Materials
We retrospectively reviewed the records of mCRPC patients who received [223Ra]RaCl
2
immediately after progressing during an AA treatment line in everyday clinical practice.
Results
We reviewed data of a consecutive series of 94 mCRPC patients. Most of the patients (85.1%) received [223Ra]RaCl
2
as second- or third-line treatment. [223Ra]RaCl
2
treatment was well-tolerated; there were only four cases of grade 3 anaemia, two cases of grade 3 leukopenia and one case of grade 3 neutropenia. The overall fracture rate is 2.1%; one fracture was recorded during the course of [223Ra]RaCl
2
treatment, and one was recorded 1 month after its end. The fractures both occurred at metastatic sites. Median OS from [223Ra]RaCl
2
start was more than 14 months regardless of the treatment line when [223Ra]RaCl
2
was administered.
Conclusion
The findings of this study show that the treatment with [223Ra]RaCl
2
immediately after AA was active and safe with a very low risk of a fracture. Thus, the present observational report makes a valuable contribution to the current debate concerning the risks and benefits of including [223Ra]RaCl
2
in the therapeutic algorithm.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>32249345</pmid><doi>10.1007/s00259-020-04796-w</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1619-7070 |
| ispartof | European journal of nuclear medicine and molecular imaging, 2020-10, Vol.47 (11), p.2633-2638 |
| issn | 1619-7070 1619-7089 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2386437740 |
| source | MEDLINE; Springer Online Journals |
| subjects | Abiraterone Acetate - adverse effects Bone Neoplasms - drug therapy Cardiology Humans Imaging Male Medicine Medicine & Public Health Nuclear Medicine Oncology Oncology – Genitourinary Original Article Orthopedics Prostatic Neoplasms, Castration-Resistant - drug therapy Radiology Radium - adverse effects Retrospective Studies Treatment Outcome |
| title | Fracture risk and survival outcomes in metastatic castration-resistant prostate cancer patients sequentially treated with abiraterone acetate and RADIUM-223 |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T15%3A21%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Fracture%20risk%20and%20survival%20outcomes%20in%20metastatic%20castration-resistant%20prostate%20cancer%20patients%20sequentially%20treated%20with%20abiraterone%20acetate%20and%20RADIUM-223&rft.jtitle=European%20journal%20of%20nuclear%20medicine%20and%20molecular%20imaging&rft.au=Caffo,%20Orazio&rft.date=2020-10-01&rft.volume=47&rft.issue=11&rft.spage=2633&rft.epage=2638&rft.pages=2633-2638&rft.issn=1619-7070&rft.eissn=1619-7089&rft_id=info:doi/10.1007/s00259-020-04796-w&rft_dat=%3Cproquest_cross%3E2386437740%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2386437740&rft_id=info:pmid/32249345&rfr_iscdi=true |